

Tong Jeffrey K
 Form 3
 January 07, 2010

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â Tong Jeffrey K

(Last) (First) (Middle)

2. Date of Event Requiring Statement

(Month/Day/Year)
 01/01/2010

3. Issuer Name and Ticker or Trading Symbol
 INFINITY PHARMACEUTICALS, INC. [INFI]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

Director 10% Owner
 Officer Other
 (give title below) (specify below)
 VP, Cor. & Product Development

C/O INFINITY
 PHARMACEUTICALS,
 INC.,Â 780 MEMORIAL
 DRIVE

(Street)

CAMBRIDGE,Â MAÂ 02139

(City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Common Stock

17,246

D Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and Expiration Date (Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security

4. Conversion or Exercise

5. Ownership Form of

6. Nature of Indirect Beneficial Ownership

Edgar Filing: Tong Jeffrey K - Form 3

| | Date Exercisable | Expiration Date | (Instr. 4) Title | Amount or Number of Shares | Price of Derivative Security | Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | (Instr. 5) |
|-----------------------------|---------------------------|-----------------|---------------------|----------------------------|------------------------------|--|------------|
| Stock Option (Right to Buy) | 05/05/2003 ⁽¹⁾ | 05/05/2013 | Common Stock | 1,203 | \$ 1.72 | D | Â |
| Stock Option (Right to Buy) | 05/10/2005 ⁽²⁾ | 05/10/2015 | Common Stock | 54,672 | \$ 2.04 | D | Â |
| Stock Option (Right to Buy) | 03/31/2006 ⁽¹⁾ | 03/31/2016 | Common Stock | 5,856 | \$ 3.48 | D | Â |
| Stock Option (Right to Buy) | Â ⁽³⁾ | 01/25/2017 | Common Stock | 42,418 | \$ 13.59 | D | Â |
| Stock Option (Right to Buy) | Â ⁽⁴⁾ | 12/13/2017 | Common Stock | 20,815 | \$ 9.8 | D | Â |
| Stock Option (Right to Buy) | Â ⁽⁵⁾ | 12/04/2018 | Common Stock | 35,415 | \$ 7.18 | D | Â |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|----------------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Tong Jeffrey K C/O INFINITY PHARMACEUTICALS, INC. 780 MEMORIAL DRIVE CAMBRIDGE, MA 02139 | Â | Â | Â VP, Cor. & Product Development | Â |

Signatures

/s/ Jeffrey K
Tong

01/07/2010

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This stock option was granted under the issuer's Pre-Merger Stock Incentive Plan, which permits the early exercise of unvested stock options in exchange for shares of restricted stock that are subject to a right of repurchase by the issuer that lapses in accordance with the vesting schedule of the original option. This option is fully vested.

(2) This option was granted under the issuer's Pre-Merger Stock Incentive Plan, which permits the early exercise of unvested stock options in exchange for shares of restricted stock that are subject to a right of repurchase by the issuer that lapses in accordance with the vesting schedule of the original option. This option is currently vested as to 46,718 shares and vests as to the remaining shares in equal monthly installments through December 31, 2010.

(3) The option vests as to 1/48th of the shares on January 31, 2007 and vests as to 1/48th of the shares at the end of each calendar month thereafter.

(4)

Edgar Filing: Tong Jeffrey K - Form 3

The option vests as to 1/48th of the shares on December 31, 2007 and vests as to 1/48th of the shares at the end of each calendar month thereafter.

- (5) The option vests as to 1/48th of the shares on December 31, 2008 and vests as to 1/48th of the shares at the end of each calendar month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.